
Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.

Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Communicating to patients that they need to come to their annual checkup is important for eye doctors to convey to help treat their patients, says Ariana Levin, MD.

Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.

Although there are no means of preventing glaucoma, there are means of preventing long-term vision loss.

Experts discuss the signs and symptoms, treatment methods, and the future of glaucoma as Glaucoma Awareness Month concludes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Standard double reading did not perform as well as artificial intelligence for looking at catching cancer and reduced the rate of breast cancer diagnosis by 12%.

The future of treating glaucoma relies on ophthalmologists and optometrists personalizing therapy to their patient, says Manjool Shah, MD.

The upcoming price negotiations are the third cycle since the Inflation Reduction Act was passed in 2022.

With the CDC’s decision to roll back recommendations to vaccinate for several conditions, questions have arisen as to what that may mean in the US.

Health outcomes and inpatient costs improved for veterans when the federal government invested in preventing homelessness.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A review of case studies found that patients with double seronegative myasthenia gravis (MG) had similarities in the ways their condition presented.

Experts discuss the impact of biomarker testing on GU and lung cancers, as well as myeloma, emphasizing its role in personalized treatment and patient care advancements.

The CEOs of UnitedHealth Group, CVS Health, Elevance Health, The Cigna Group, and Ascendiun attended hearings in the House of Representatives all day Thursday.

Minimizing the use of corticosteroids in clinical practice can help to prevent any long-term impact on patients with myasthenia gravis.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Visual acuity and central macular thickness improved in patients with diabetic macular edema who used combined phacoemulsification and intravitreal dexamethasone implants.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

The maternal morbidity was compared between states that passed laws to regulate providers with states that did not.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The House voted to extend the insurance subsidies under the Affordable Care Act (ACA), but the bill could face problems in the Senate.

Although most clinicians used intraocular pressure (IOP) as a continuous risk factor in glaucoma treatment decisions, the historical cutoff may still be used.

These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

The treatment was compared with adagrasib in second- and subsequent-line treatment, with sotarasib coming out on top based on current efficacy data.

Medicare HIV cases are projected to double by 2035, with cumulative costs reaching $195.6 billion and creating critical challenges for federal funding.

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.